D
NervGen Pharma Corp.
NGEN.V
TSX
D
Sell
12/24/2024Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 12/24/2024 due to an increase in the volatility index.
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 12/24/2024 due to an increase in the volatility index.
E
Sell
12/6/2024Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 12/6/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 38.07% from -$3.06M to -$4.22M, EBIT declined 19.66% from -$4.39M to -$5.25M, and the quick ratio declined from 1.73 to 1.59.
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 12/6/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 38.07% from -$3.06M to -$4.22M, EBIT declined 19.66% from -$4.39M to -$5.25M, and the quick ratio declined from 1.73 to 1.59.
D
Sell
7/2/2024Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 7/2/2024 due to an increase in the volatility index.
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 7/2/2024 due to an increase in the volatility index.
E
Sell
6/17/2024Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 6/17/2024 due to a decline in the volatility index.
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 6/17/2024 due to a decline in the volatility index.
D
Sell
10/17/2023Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 10/17/2023 due to an increase in the volatility index, total return index and valuation index.
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 10/17/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
9/28/2023Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 9/28/2023 due to a decline in the volatility index.
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 9/28/2023 due to a decline in the volatility index.
D
Sell
9/13/2023Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 9/13/2023 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 57.92% from -$3.54M to -$1.49M.
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 9/13/2023 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 57.92% from -$3.54M to -$1.49M.
E
Sell
4/21/2023Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index.
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 4/21/2023 due to a decline in the volatility index.
D
Sell
4/5/2023Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 4/5/2023 due to an increase in the volatility index and total return index.
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E+ on 4/5/2023 due to an increase in the volatility index and total return index.
E
Sell
3/29/2023Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 3/29/2023 due to a decline in the volatility index and total return index.
NervGen Pharma Corp. (NGEN.V) was downgraded to E+ from D- on 3/29/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 03/14/2023.
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index and volatility index.
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 2/8/2023 due to a major decline in the total return index and volatility index.
D
Sell
5/31/2022Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 5/31/2022 due to an increase in the total return index.
D
Sell
5/13/2022Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index and solvency index. Operating cash flow declined 47.22% from -$2.27M to -$3.34M, the quick ratio declined from 15.76 to 11.52, and EBIT declined 20.05% from -$3.29M to -$3.95M.
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 5/13/2022 due to a decline in the growth index and solvency index. Operating cash flow declined 47.22% from -$2.27M to -$3.34M, the quick ratio declined from 15.76 to 11.52, and EBIT declined 20.05% from -$3.29M to -$3.95M.
D
Sell
5/5/2022Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index.
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 5/5/2022 due to an increase in the volatility index.
D
Sell
4/20/2022Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 4/20/2022 due to a significant decline in the total return index.
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 4/20/2022 due to a significant decline in the total return index.
D
Sell
11/22/2021Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 11/22/2021 due to an increase in the total return index, growth index and solvency index. Operating cash flow increased 6.87% from -$1.72M to -$1.6M, and the quick ratio increased from 7.34 to 7.64.
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 11/22/2021 due to an increase in the total return index, growth index and solvency index. Operating cash flow increased 6.87% from -$1.72M to -$1.6M, and the quick ratio increased from 7.34 to 7.64.
D
Sell
11/8/2021Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index, valuation index and solvency index. Operating cash flow declined 68.95% from -$1.02M to -$1.72M, EBIT declined 27.9% from -$1.76M to -$2.25M, and earnings per share declined from -$0.0501 to -$0.0591.
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index, valuation index and solvency index. Operating cash flow declined 68.95% from -$1.02M to -$1.72M, EBIT declined 27.9% from -$1.76M to -$2.25M, and earnings per share declined from -$0.0501 to -$0.0591.
D
Sell
11/20/2020Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 11/20/2020 due to a major increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.33 to 23.68, earnings per share increased from -$0.0624 to -$0.0479, and EBIT increased 15.27% from -$1.89M to -$1.6M.
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 11/20/2020 due to a major increase in the growth index, volatility index and solvency index. The quick ratio increased from 6.33 to 23.68, earnings per share increased from -$0.0624 to -$0.0479, and EBIT increased 15.27% from -$1.89M to -$1.6M.
D
Sell
10/13/2020Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 10/13/2020 due to a noticeable decline in the growth index and volatility index. EBIT declined 36.21% from -$1.39M to -$1.89M, and earnings per share declined from -$0.047 to -$0.0624.
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 10/13/2020 due to a noticeable decline in the growth index and volatility index. EBIT declined 36.21% from -$1.39M to -$1.89M, and earnings per share declined from -$0.047 to -$0.0624.
D
Sell
6/2/2020Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index. Earnings per share increased from -$0.0762 to -$0.047, EBIT increased 36.85% from -$2.2M to -$1.39M, and operating cash flow increased 6.74% from -$1.52M to -$1.42M.
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index. Earnings per share increased from -$0.0762 to -$0.047, EBIT increased 36.85% from -$2.2M to -$1.39M, and operating cash flow increased 6.74% from -$1.52M to -$1.42M.
D
Sell
5/28/2020Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 5/28/2020 due to a decline in the total return index, volatility index and growth index.
NervGen Pharma Corp. (NGEN.V) was downgraded to D- from D on 5/28/2020 due to a decline in the total return index, volatility index and growth index.
D
Sell
5/1/2020Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and growth index. Operating cash flow increased 6.16% from -$1.62M to -$1.52M.
NervGen Pharma Corp. (NGEN.V) was upgraded to D from D- on 5/1/2020 due to an increase in the total return index, volatility index and growth index. Operating cash flow increased 6.16% from -$1.62M to -$1.52M.
D
Sell
12/2/2019Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E on 12/2/2019 due to an increase in the volatility index and total return index.
NervGen Pharma Corp. (NGEN.V) was upgraded to D- from E on 12/2/2019 due to an increase in the volatility index and total return index.
E
Sell
9/3/2019Upgraded
NervGen Pharma Corp. (NGEN.V) was upgraded to E from E- on 9/3/2019 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from -$0.1177 to -$0.0412, EBIT increased 48.41% from -$2.27M to -$1.17M, and operating cash flow increased 47.97% from -$1.95M to -$1.01M.
NervGen Pharma Corp. (NGEN.V) was upgraded to E from E- on 9/3/2019 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from -$0.1177 to -$0.0412, EBIT increased 48.41% from -$2.27M to -$1.17M, and operating cash flow increased 47.97% from -$1.95M to -$1.01M.
E
Sell
6/13/2019Downgrade
NervGen Pharma Corp. (NGEN.V) was downgraded to E- from E on 6/13/2019 due to a decline in the volatility index.
NervGen Pharma Corp. (NGEN.V) was downgraded to E- from E on 6/13/2019 due to a decline in the volatility index.
E
Sell
6/7/2019None
NervGen Pharma Corp. (NGEN.V) was downgraded to E from U on 06/07/2019.
NervGen Pharma Corp. (NGEN.V) was downgraded to E from U on 06/07/2019.
